Enhancing Domestic Drug Manufacturing Competitiveness Act
Summary
HB1405, titled the Enhancing Domestic Drug Manufacturing Competitiveness Act, would require the Comptroller General (through the Government Accountability Office) to study the regulatory barriers that make it harder to expand or site new pharmaceutical manufacturing facilities in the United States. The study must identify barriers that increase time and cost, compare U.S. regulatory conditions with those in other countries, and examine how regulations may affect pharmaceutical supply chain resiliency.
The bill also directs the study to consider what actions regulators could take to reduce delays, including expediting reviews, inspections, and approvals for new facilities or changes to existing facilities. In addition, the Comptroller General must consult stakeholders, look for promising technological or manufacturing-process solutions that could help address the barriers, and identify policies needed to support those solutions. A report to Congress would be due within one year of enactment and must include findings and recommendations for streamlining regulation and encouraging more domestic pharmaceutical manufacturing.
Impact
If enacted, the bill would not directly change substantive environmental, health, or manufacturing laws; instead, it would create a federal GAO study and reporting requirement focused on regulatory barriers to domestic drug manufacturing. Its practical effect would be to generate congressional findings and recommendations that could later inform legislation, agency rulemaking, or permitting reforms affecting pharmaceutical plants, inspections, approvals, and supply-chain policy. The measure primarily affects federal regulators, pharmaceutical manufacturers, and stakeholders involved in siting or expanding drug production facilities in the United States.
Sentiment
The available context suggests generally favorable sentiment toward the bill, or at least toward its policy goal of strengthening domestic pharmaceutical manufacturing. The bill was introduced by its sponsors and referred to committee without recorded votes or committee debate in the provided materials, so there is no evidence of formal opposition in the record supplied. The framing of the bill emphasizes competitiveness, resiliency, and streamlining, which are typically presented as pro-manufacturing and pro-supply-chain measures.
Contention
The main potential point of contention is the bill’s focus on regulatory barriers, especially environmental and other permitting requirements, which some may view as necessary safeguards while others may see them as obstacles to domestic production. The study specifically asks whether regulations delay projects and increase costs relative to other countries, which could draw disagreement from environmental advocates, public health stakeholders, and industry groups over how to balance faster approvals with oversight. Another possible area of debate is whether supply-chain resiliency should justify expedited reviews and reduced regulatory burdens for pharmaceutical facilities.
Creates the Steel and Advanced Manufacturing Competitiveness Act; creates Steel Industry Relief and Investment Grant Program; creates the Manufacturing Innovation and Modernization Tax Credit
An act to add Article 8 (commencing with Section 12100.80) to Chapter 1.6 of Part 2 of Division 3 of Title 2 of, and to add Article 12 (commencing with Section 63049.80) to Chapter 2 of Division 1 of Title 6.7 of, the Government Code, relating to electricity, and making an appropriation therefor.